These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 27981583)
1. Cross-seeding between Aβ40 and Aβ42 in Alzheimer's disease. Tran J; Chang D; Hsu F; Wang H; Guo Z FEBS Lett; 2017 Jan; 591(1):177-185. PubMed ID: 27981583 [TBL] [Abstract][Full Text] [Related]
2. A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling. Gu L; Tran J; Jiang L; Guo Z J Struct Biol; 2016 Apr; 194(1):61-7. PubMed ID: 26827680 [TBL] [Abstract][Full Text] [Related]
3. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway. Chang YJ; Chen YR FEBS J; 2014 Jun; 281(11):2674-87. PubMed ID: 24720730 [TBL] [Abstract][Full Text] [Related]
4. Cross-seeding of WT amyloid-β with Arctic but not Italian familial mutants accelerates fibril formation in Alzheimer's disease. Liang R; Tian Y; Viles JH J Biol Chem; 2022 Jul; 298(7):102071. PubMed ID: 35643314 [TBL] [Abstract][Full Text] [Related]
5. Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes. Qiang W; Yau WM; Lu JX; Collinge J; Tycko R Nature; 2017 Jan; 541(7636):217-221. PubMed ID: 28052060 [TBL] [Abstract][Full Text] [Related]
6. Iron treatment inhibits Aβ42 deposition in vivo and reduces Aβ42/Aβ40 ratio. Shen X; Liu J; Fujita Y; Liu S; Maeda T; Kikuchi K; Obara T; Takebe A; Sayama R; Takahashi T; Matsue A; Sera K; Michikawa M; Komano H; Zou K Biochem Biophys Res Commun; 2019 May; 512(4):653-658. PubMed ID: 30791980 [TBL] [Abstract][Full Text] [Related]
7. N-Terminus Binding Preference for Either Tanshinone or Analogue in Both Inhibition of Amyloid Aggregation and Disaggregation of Preformed Amyloid Fibrils-Toward Introducing a Kind of Novel Anti-Alzheimer Compounds. Dong M; Zhao W; Hu D; Ai H; Kang B ACS Chem Neurosci; 2017 Jul; 8(7):1577-1588. PubMed ID: 28406293 [TBL] [Abstract][Full Text] [Related]
8. Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40. Beach TG; Maarouf CL; Intorcia A; Sue LI; Serrano GE; Lu M; Joshi A; Pontecorvo MJ; Roher AE J Alzheimers Dis; 2018; 61(4):1509-1516. PubMed ID: 29376867 [TBL] [Abstract][Full Text] [Related]
9. Cross-seeding effects of amyloid β-protein and α-synuclein. Ono K; Takahashi R; Ikeda T; Yamada M J Neurochem; 2012 Sep; 122(5):883-90. PubMed ID: 22734715 [TBL] [Abstract][Full Text] [Related]
10. New Evidence on a Distinction between Aβ40 and Aβ42 Amyloids: Thioflavin T Binding Modes, Clustering Tendency, Degradation Resistance, and Cross-Seeding. Sulatskaya AI; Rychkov GN; Sulatsky MI; Mikhailova EV; Melnikova NM; Andozhskaya VS; Kuznetsova IM; Turoverov KK Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628325 [TBL] [Abstract][Full Text] [Related]
11. Dissecting the Molecular Mechanisms of the Co-Aggregation of Aβ40 and Aβ42 Peptides: A REMD Simulation Study. Li X; Yang Z; Chen Y; Zhang S; Wei G; Zhang L J Phys Chem B; 2023 May; 127(18):4050-4060. PubMed ID: 37126408 [TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. Gu L; Guo Z J Neurochem; 2013 Aug; 126(3):305-11. PubMed ID: 23406382 [TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Aβ42 and Aβ40 form mixed oligomers with direct molecular interactions. Gu L; Guo Z Biochem Biophys Res Commun; 2021 Jan; 534():292-296. PubMed ID: 33272573 [TBL] [Abstract][Full Text] [Related]
14. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Meisl G; Yang X; Hellstrand E; Frohm B; Kirkegaard JB; Cohen SI; Dobson CM; Linse S; Knowles TP Proc Natl Acad Sci U S A; 2014 Jul; 111(26):9384-9. PubMed ID: 24938782 [TBL] [Abstract][Full Text] [Related]
15. Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42. Jäkel L; Biemans EALM; Klijn CJM; Kuiperij HB; Verbeek MM Mol Neurobiol; 2020 Apr; 57(4):2131-2141. PubMed ID: 31953617 [TBL] [Abstract][Full Text] [Related]
16. E22G Aβ40 fibril structure and kinetics illuminate how Aβ40 rather than Aβ42 triggers familial Alzheimer's. Tehrani MJ; Matsuda I; Yamagata A; Kodama Y; Matsunaga T; Sato M; Toyooka K; McElheny D; Kobayashi N; Shirouzu M; Ishii Y Nat Commun; 2024 Aug; 15(1):7045. PubMed ID: 39147751 [TBL] [Abstract][Full Text] [Related]
17. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. Jan A; Gokce O; Luthi-Carter R; Lashuel HA J Biol Chem; 2008 Oct; 283(42):28176-89. PubMed ID: 18694930 [TBL] [Abstract][Full Text] [Related]
18. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium. Wang Z; Sharda N; Omtri RS; Li L; Kandimalla KK Mol Pharmacol; 2023 Nov; 104(5):203-213. PubMed ID: 37541759 [TBL] [Abstract][Full Text] [Related]
19. Monomer Dynamics of Alzheimer Peptides and Kinetic Control of Early Aggregation in Alzheimer's Disease. Acharya S; Srivastava KR; Nagarajan S; Lapidus LJ Chemphyschem; 2016 Nov; 17(21):3470-3479. PubMed ID: 27490673 [TBL] [Abstract][Full Text] [Related]
20. Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms. Im D; Choi TS BMB Rep; 2024 Jun; 57(6):263-272. PubMed ID: 38835114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]